Tabrecta (capmatinib) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tabrecta is used in ...

If you’re looking at treatment options for a certain kind of lung cancer, your doctor might suggest Tabrecta (capmatinib). Learning about the possible side effects can help you know what to ...

Novartis has exclusive worldwide development and commercialization rights to Tabrecta The approval of Tabrecta is based on results from the pivotal GEOMETRY mono-1 study. In the METex14 population ...

Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14 ...

EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta ™ (capmatinib, formerly INC280), an oral MET inhibitor ...

“One FDA approval that we were quite excited about (is Tabrecta). And I've actually already put some patients on it; it's a very good drug,” Dr. Timothy Burns said in a recent interview. Despite the ...

Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta ...

Incyte, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) ...

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung ...

Tabrecta (capmatinib) is approved in several countries including the US, Switzerland and Japan. It is the number one prescribed targeted therapy for patients with advanced NSCLC with alterations ...

The agency Wednesday approved Tabrecta (capmatinib) for metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations, regardless of whether they’ve tried other ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta™ (capmatinib) for MET exon 14 skipping ...